Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + prochlorperazine for advanced cutaneous squamous cell carcinoma in solid organ transplant recipients
ACTRN12624000917538Phase 2Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and prochlorperazine in cutaneous squamous cell carcinoma (cSCC), sponsored by The University of Queensland. Primary endpoint: Disease control rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
cetuximabprochlorperazine
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12624000917538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000917538.